Tumor stiffness measured by shear-wave elastography: association with disease-free survival in women with early-stage breast cancer

Abstract

Objective: To determine whether shear-wave elastography (SWE)-measured tumor stiffness is associated with disease-free survival in females with early-stage invasive breast cancer. Methods: This retrospective study included 202 consecutive females (mean age, 52.9 years; range, 25–84 years) with newly diagnosed T1–two breast cancer who underwent preoperative SWE between April 2015 and January 2016. Tumor stiffness was assessed and quantitative SWE features of each breast lesion were obtained by a breast radiologist. Cox proportional hazards models were used to identify associations between SWE features and disease-free survival after adjusting for clinicopathologic factors. Results: Fifteen (7.4%) patients exhibited recurrence after a median follow-up of 56 months. Mean (Emean), minimum, and maximum elasticity values were higher in females with recurrence than in those without recurrence (184.4, 138.3, and 210.5 kPa vs 134.9, 101.7, and 163.6 kPa, respectively; p = 0.005, p = 0.005, and p = 0.012, respectively). Receiver operating characteristics curve analysis for prediction of recurrence showed that Emean yielded the largest area under the curve (0.717) among the quantitative SWE parameters, and the optimal cut-off value was 121.7 kPa. Multivariable Cox proportional hazards analysis revealed that higher Emean (>121.7 kPa) [adjusted hazard ratio (HR), 10.01; 95% CI: 1.31–76.33; p = 0.026] and lymphovascular invasion (adjusted HR, 7.72; 95% CI: 1.74–34.26; p = 0.007) were associated with worse disease-free survival outcomes. Conclusion: Higher SWE-measured Emean was associated with worse disease-free survival in females with early-stage invasive breast cancer. Advances in knowledge: Tumor stiffness assessed with shear-wave elastography might serve as a quantitative imaging biomarker of disease-free survival in females with T1–two breast cancer.

Innovative Experimental Ultrasound and US-Related Techniques Using the Murine Model in Pancreatic Ductal Adenocarcinoma: A Systematic Review

“…Ultrasound elastography can measure tissue stiffness noninvasively and can be performed during theroutine imaging of some tumours. Among the techniques used to acquire elastographic data, shear-wave elastography (SWE) allows for more reproducible, quantitative measurement of tissue stiffness and yields quantitative SWE parameters, such as the minimum, mean, and maximum elasticity in a region of interest [132]. In addition, elastography aims to quantitatively image the Young's E modulus, the physical parameter corresponding to the stiffness.…”

Tumor-Infiltrating Lymphocyte Level Consistently Correlates with Lower Stiffness Measured by Shear-Wave Elastography: Subtype-Specific Analysis of Its Implication in Breast Cancer

“…Higher stiffness has shown significant correlation with poor prognostic factors, including a larger tumor size, lymphovascular invasion (LVI), a higher histologic grade (HG), lymph node (LN) metastasis, a triplenegative status, and a high Ki67 labeling index (LI) [7][8][9][10][11][12]. From a prognostic perspective, higher stiffness has been linked to worse disease-free survival in patients with early breast cancer [13].…”

Strain ultrasonic elastography imaging features of locally advanced breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival

“…Tumor stiffness has been shown to be significantly correlated with tumor growth and aggression, and high mean stiffness values of breast cancers were reported to be significantly correlated with large invasive size and high histologic grade [ 9 ]. Higher tumor stiffness assessed by shear-wave elastography (SWE) was associated with worse disease-free survival in patients with early-stage invasive breast cancer [ 16 ]. Ultrasonic elastography may be an ideal investigative modality for early prediction of response to chemotherapy and recurrence-free survival (RFS) in breast cancer patients without exposing the patients to any risk of radiation and external contrast agent.…”